SynthesisOrphanet journal of rare diseases2026
Mitochondrial mutation status, symptom prevalence, and neuroimaging characteristics in MELAS: a systematic review and meta analysis.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a rare mitochondrial disorder characterized by a wide range of systemic manifestations. MELAS is challenging to diagnose in its early stages and currently lacks targeted treatments. This systematic review and meta-analysis aim to validate the mitochondrial 3243A > G (m.3243A > G) mutation status, symptom prevalence, and neuroimaging characteristics in patients with MELAS. The review also seeks to consolidate and clarify the pathogenic pathways of MELAS while pinpointing potential therapeutic targets. MAIN BODY: We searched four databases for relevant studies. Study selection, data extraction, and quality assessment using the JBI (Joanna Briggs Institute) scale were performed by two reviewers. We conducted meta-analyses to estimate the pooled proportions for genetic, symptomatic, and imaging features using the random-effects generalized linear mixed model. In addition, seven MELAS-related pathways were researched, and their gene information was expanded through computational retrieval from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases. A total of 13 studies involving 988 subjects were included, covering one mutant gene (m.3243A > G), ten clinical symptoms, and four imaging features. The meta-analyses showed a pooled m.3243A > G mutation prevalence of 78% (95% CI: 68%, 86%). The most frequent clinical manifestations were stroke-like episodes (99%; 95% CI: 29%, 100%), seizures (89%; 95% CI: 65%, 97%), and elevated lactate (81%; 95% CI: 50%, 95%). The temporal lobe was the most commonly affected brain region on imaging (87%; 95% CI: 13%, 100%). Pathway analysis revealed mitophagy/autophagy, ROS generation, and energy metabolism as core mechanisms in MELAS, with MNRR1, L-arginine, PI3K-AKT-mTOR, and ETC as potential therapeutic targets.
conclusionThis study collects evidence for the confirmatory diagnosis of MELAS, integrating its genetic, clinical, and neuroimaging spectra. Furthermore, by elucidating the core pathological network, our work provides a potential framework for developing multi-targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.